Top > Search of International Patents > CANCER THERAPEUTIC DRUG AND CANCER TREATMENT METHOD

CANCER THERAPEUTIC DRUG AND CANCER TREATMENT METHOD

Foreign code F170008955
File No. (S2015-1669-N0)
Posted date Feb 16, 2017
Country WIPO
International application number 2016JP066393
International publication number WO 2016208348
Date of international filing Jun 2, 2016
Date of international publication Dec 29, 2016
Priority data
  • P2015-128139 (Jun 25, 2015) JP
Title CANCER THERAPEUTIC DRUG AND CANCER TREATMENT METHOD
Abstract [Problem] To clarify the role of stem cell regulation factors, including Matrin-3, in cancer showing neural differentiation such as small cell cancer in the lung, and to develop a drug or the like which is useful for the treatment of cancer with relying on the role.
[Solution] In some types of cancer which show a differentiation ability among various types of cancer which have a cancer stem cell regulation mechanism, both a stem cell-maintaining factor and a stem cell differentiation-accelerating factor are expressed at higher levels compared with normal cells and these factors keep a specific balance therebetween. In undifferentiated types of cancer among the above-mentioned various types of cancer, a stem cell-maintaining factor is expressed at a higher level compared with normal cells and these factors keep a specific balance therebetween. In some types of cancer in which the cancer stem cell regulation mechanism is present, there is a specific balance between these stem cell-regulating factors which is different from that in normal cells. In a cancer therapeutic drug and a cancer treatment method according to the present invention, the balance between the above-menioned stem cell-regulating factors is broken down to inhibit the proliferation ability of cancer.
Outline of related art and contending technology BACKGROUND ART
Is small cell lung cancer, compared to the other of the cancer cell and the small sizes of the cells, so named. Is characterized by a small cell lung cancer, lung cancer progress faster in the thin, poorly differentiated in rapidly proliferating. Therefore, small cell lung cancer, early stage of the transition to the lymph node or other organ seen, in most cases, can be found in the state of advanced cancer. As a result, the small cell lung cancer, compared to other cancers, are known to have a high mortality rate.
The current, for treatment of small cell lung cancer, anticancer radiation treatment is being performed. However, these treatments are, in an extension of the life expectancy contributes, in a complete cure is extremely difficult at present. In small cell lung cancer, early detection of small cell lung cancer, suppression of growth of the tumor, if it is possible to suppress metastasis, the treatment result is believed to improve dramatically. However, the molecular basis of small cell lung cancer often will be an as-yet point, higher therapeutic effect can be expected in the present situation there is no effective therapy is.
Having such a feature is small cell lung cancer, is further characterized, which is known to show neuronal differentiation. Neural differentiation and, to maintain the stem cell is a stem cell factors, into cells of the nervous system phenomenon. The manner in which the neural differentiation in controlled studies have been conducted on the at least one but, not clearly. In addition, the neuronal differentiation, small cell lung cancer is determined to be associated with the condition does not become apparent, of course, not connected to the development of a therapeutic agent.
On the other hand, is Matrin-3, recently, an important finding can be reported THs, attention has been paid molecule. Matrin-3 is nuclear protein which 125-kDa (non-patent document 1, non-patent document 2), chromatin organisation, DNA replication, RNA processing have functions such as (non-patent document 3) are known. Matrin-3 is, up to now, most of the analyzed Neuroscience field was found to be not taken. However, recently Matrin-3 gene mutations on the grounds that the familial amyotrophic lateral sclerosis (non-patent document 4), the network Matrin-3, homeodomain transcriptional program to be essential for the (non-patent document 5) and the like have been reported.
Scope of claims (In Japanese)[請求項1]
分化能を示す癌,並びに,未分化性を有する癌において,癌幹細胞制御機構を破綻させることにより,癌細胞の増殖を抑制することを特徴とする癌治療薬剤
[請求項2]
癌幹細胞制御機構の破綻が,幹細胞制御因子もしくはリン酸化幹細胞制御因子の発現量を抑制することにより行われることを特徴とする請求項1に記載の癌治療薬剤
[請求項3]
癌幹細胞制御機構の破綻が,幹細胞制御因子のリン酸化を阻害することにより行われることを特徴とする請求項1又は2に記載の癌治療薬剤
[請求項4]
前記幹細胞制御因子が,癌細胞における核内に存在する幹細胞制御因子であることを特徴とする請求項1から3に記載の癌治療薬剤
[請求項5]
前記幹細胞制御因子の発現量の抑制が,抗幹細胞制御因子抗体を有効成分とする薬剤によりなされることを特徴とする請求項2に記載の癌治療薬剤
[請求項6]
前記リン酸化幹細胞制御因子の発現量の抑制が,抗リン酸化幹細胞制御因子抗体を有効成分とする薬剤によりなされることを特徴とする請求項2に記載の癌治療薬剤
[請求項7]
前記幹細胞制御因子の発現量の抑制が,幹細胞制御因子に対するsiRNAを有効成分とする薬剤によりなされることを特徴とする請求項2に記載の癌治療薬剤
[請求項8]
前記siRNAが,配列番号1から6に記載される配列であることを特徴とする請求項7に記載の癌治療薬剤
[請求項9]
前記幹細胞制御因子が,Matrin-3,INI1,hnRNPK,MBD3,SFRS3のいずれか又は複数から選択されることを特徴とする請求項1から8に記載の癌治療薬剤
[請求項10]
分化能を示す癌,並びに,未分化性を有する癌が,神経内分泌腫瘍であることを特徴とする請求項1から9に記載の癌治療薬剤
[請求項11]
分化能を示す癌,並びに,未分化性を有する癌が,肺小細胞癌,白血病,乳癌,大腸癌,胃癌,直腸癌,皮膚癌,前立腺癌,卵巣癌,子宮体癌,膵臓癌,骨肉腫,神経芽細胞腫癌のいずれかから選択されることを特徴とする請求項1から9に記載の癌治療薬剤
[請求項12]
分化能を示す癌,並びに,未分化性を有する癌において,癌幹細胞制御機構を破綻させることにより,癌細胞の増殖を抑制することを特徴とする癌の治療方法
[請求項13]
癌組織における幹細胞制御因子の発現を調べることにより,癌治療薬の治療効果を予測することを特徴とする癌の体外診断用キット
[請求項14]
生検により採取された癌細胞を含む生検サンプルから組織切片を作製し,幹細胞制御因子の免疫染色を行うことにより,幹細胞制御因子の発現を調べ,癌治療薬剤の治療効果を予測することを特徴とする治療効果予測方法
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
  • Inventor
  • NIIMORI Kanako
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or telephone if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close